Dong-A ST’s licensing-out treatment is under new drug application in the U.S.
Published: 2013-10-25 06:56:00
Updated: 2013-10-25 06:56:00
Cubist Pharmaceuticals, Inc., a new U.S. partner of Dong-A ST, said on Tuesday that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic tedizolid phosphate (TR-701).
Cubist added tedizolid phosphate to its...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
